Home » Topics » BioWorld Science

BioWorld Science
RSS

Bristol-Myers Squibb: Q3 1997 highlights

Nov. 18, 1997

Merck & Co. isolates novel antifungal agent with potent, broad-spectrum activity

Nov. 18, 1997

Second-generation, highly selective COX-2 inhibitors developed at Merck

Nov. 18, 1997

LXR's patented drug screening technology yields two novel apoptosis-suppressing agents

Nov. 18, 1997

Second report of clinical efficacy for rotavirus vaccine

Nov. 18, 1997

SomatoKine shows potential for the treatment of osteoporosis

Nov. 18, 1997

FDA clears new Tilade formulation

Nov. 18, 1997

TpP, FiF introduced to medical community at major trade show

Nov. 18, 1997

Safety, immunogenicity and efficacy of anti-TNF antibody in RA patients

Nov. 18, 1997

Data presented on Shionogi's S-2150

Nov. 18, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...